{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:10:26Z","timestamp":1780614626742,"version":"3.54.1"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H04791"],"award-info":[{"award-number":["JP21H04791"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H05113"],"award-info":[{"award-number":["JP21H05113"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H05037"],"award-info":[{"award-number":["JP21H05037"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJFR215T"],"award-info":[{"award-number":["JPMJFR215T"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJMS2023"],"award-info":[{"award-number":["JPMJMS2023"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ama121038"],"award-info":[{"award-number":["JP22ama121038"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22zf0127007"],"award-info":[{"award-number":["JP22zf0127007"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Loss-of-function mutations in the type 2 vasopressin receptor (V2R) are a major cause of congenital nephrogenic diabetes insipidus (cNDI). In the context of partial cNDI, the response to desmopressin (dDAVP) is partially, but not entirely, diminished. For those with the partial cNDI, restoration of V2R function would offer a prospective therapeutic approach. In this study, we revealed that OPC-51803 (OPC5) and its structurally related V2R agonists could functionally restore V2R mutants causing partial cNDI by inducing prolonged signal activation. The OPC5-related agonists exhibited functional selectivity by inducing signaling through the G<jats:sub>s<\/jats:sub>-cAMP pathway while not recruiting \u03b2-arrestin1\/2. We found that six cNDI-related V2R partial mutants (V88<jats:sup>2.53<\/jats:sup>M, Y128<jats:sup>3.41<\/jats:sup>S, L161<jats:sup>4.47<\/jats:sup>P, T273<jats:sup>6.37<\/jats:sup>M, S329<jats:sup>8.47<\/jats:sup>R and S333<jats:sup>8.51<\/jats:sup>del) displayed varying degrees of plasma membrane expression levels and exhibited moderately impaired signaling function. Several OPC5-related agonists induced higher cAMP responses than AVP at V2R mutants after prolonged agonist stimulation, suggesting their potential effectiveness in compensating impaired V2R-mediated function. Furthermore, docking analysis revealed that the differential interaction of agonists with L312<jats:sup>7.40<\/jats:sup> caused altered coordination of TM7, potentially contributing to the functional selectivity of signaling. These findings suggest that nonpeptide V2R agonists could hold promise as potential drug candidates for addressing partial cNDI.<\/jats:p>","DOI":"10.1371\/journal.pone.0303507","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T17:31:36Z","timestamp":1715794296000},"page":"e0303507","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants"],"prefix":"10.1371","volume":"19","author":[{"given":"Ritsuki","family":"Kuramoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Kise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-8619","authenticated-orcid":true,"given":"Kouki","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-0609","authenticated-orcid":true,"given":"Tatsuya","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-4049","authenticated-orcid":true,"given":"Asuka","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"pone.0303507.ref001","author":"DG Bichet","year":"2016","journal-title":"Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant)"},{"key":"pone.0303507.ref002","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrneph.2015.89","article-title":"Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus","volume":"11","author":"D Bockenhauer","year":"2015","journal-title":"Nature Reviews Nephrology"},{"key":"pone.0303507.ref003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/bs.vh.2019.08.012","article-title":"V2 vasopressin receptor mutations","volume":"113","author":"N Makita","year":"2020","journal-title":"Vitam Horm"},{"key":"pone.0303507.ref004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2007.03054.x","article-title":"Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene","volume":"68","author":"M F\u00e6rch","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"pone.0303507.ref005","doi-asserted-by":"crossref","first-page":"p23","DOI":"10.1159\/000320117","article-title":"Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases","volume":"116","author":"D Bockenhauer","year":"2010","journal-title":"Nephron Physiol"},{"key":"pone.0303507.ref006","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1074\/jbc.M111.268797","article-title":"V2 Vasopressin Receptor (V2R) Mutations in Partial Nephrogenic Diabetes Insipidus Highlight Protean Agonism of V2R Antagonists","volume":"287","author":"K Takahashi","year":"2012","journal-title":"Journal of Biological Chemistry"},{"key":"pone.0303507.ref007","doi-asserted-by":"crossref","first-page":"22460","DOI":"10.1074\/jbc.M116.733220","article-title":"Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist","volume":"291","author":"N Makita","year":"2016","journal-title":"Journal of Biological Chemistry"},{"key":"pone.0303507.ref008","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.metabol.2012.01.005","article-title":"Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: A case report and review of the literature","volume":"61","author":"V Neocleous","year":"2012","journal-title":"Metabolism"},{"key":"pone.0303507.ref009","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00085.2012","article-title":"New insights into the dynamic regulation of water and acid-base balance by renal epithelial cells","volume":"302","author":"D Brown","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"pone.0303507.ref010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41581-021-00447-x","article-title":"Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases","volume":"17","author":"ETB Olesen","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"pone.0303507.ref011","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1681\/ASN.2008121289","article-title":"Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus","volume":"20","author":"F Jean-Alphonse","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"pone.0303507.ref012","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.1201093109","article-title":"Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy","volume":"109","author":"R Rahmeh","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0303507.ref013","article-title":"Antidiuretic Effects of a Nonpeptide Vasopressin V2-Receptor Agonist, OPC-51803, Administered Orally to Rats","volume":"295","author":"S Nakamura","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"pone.0303507.ref014","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bmcl.2005.10.107","article-title":"Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists","volume":"16","author":"AA Failli","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"pone.0303507.ref015","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1021\/jm8008162","article-title":"New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists","volume":"51","author":"CM Yea","year":"2008","journal-title":"J Med Chem"},{"key":"pone.0303507.ref016","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1254\/jphs.93.484","article-title":"Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats","volume":"93","author":"S Nakamura","year":"2003","journal-title":"J Pharmacol Sci"},{"key":"pone.0303507.ref017","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1254\/jphs.94.426","article-title":"Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs","volume":"94","author":"S Nakamura","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"pone.0303507.ref018","doi-asserted-by":"crossref","first-page":"16683","DOI":"10.1074\/jbc.270.28.16683","article-title":"Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor","volume":"270","author":"SC Sealfon","year":"1995","journal-title":"J Biol Chem"},{"key":"pone.0303507.ref019","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07094-0","article-title":"Crystal structures of human ETB receptor provide mechanistic insight into receptor activation and partial activation","volume":"9","author":"W Shihoya","year":"2018","journal-title":"Nat Commun"},{"key":"pone.0303507.ref020","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cell.2019.04.044","article-title":"Illuminating G-Protein-Coupling Selectivity of GPCRs","volume":"177","author":"A Inoue","year":"2019","journal-title":"Cell"},{"key":"pone.0303507.ref021","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37233-1","article-title":"Function and dynamics of the intrinsically disordered carboxyl terminus of \u03b22 adrenergic receptor","volume":"14","author":"J Heng","year":"2023","journal-title":"Nat Commun"},{"key":"pone.0303507.ref022","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41422-021-00480-2","article-title":"Molecular basis of ligand recognition and activation of human V2 vasopressin receptor","volume":"31","author":"F Zhou","year":"2021","journal-title":"Cell Research"},{"key":"pone.0303507.ref023","doi-asserted-by":"crossref","first-page":"1004586","DOI":"10.1371\/journal.pcbi.1004586","article-title":"AutoDockFR: Advances in Protein-Ligand Docking with Explicitly Specified Binding Site Flexibility","volume":"11","author":"PA Ravindranath","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"pone.0303507.ref024","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0968-0896(99)00101-7","article-title":"7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist","volume":"7","author":"K Kondo","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"pone.0303507.ref025","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.bjp.0703221","article-title":"Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes","volume":"129","author":"S Nakamura","year":"2000","journal-title":"Br J Pharmacol"},{"key":"pone.0303507.ref026","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/ajprenal.00404.2004","article-title":"Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model","volume":"289","author":"JH Robben","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"pone.0303507.ref027","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"V Bernier","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"pone.0303507.ref028","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg5628","article-title":"Cryo-electron microscopy structure of the antidiuretic hormone arginine-vasopressin V2 receptor signaling complex","volume":"7","author":"J Bous","year":"2021","journal-title":"Sci Adv"},{"key":"pone.0303507.ref029","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7761","article-title":"Structure of the vasopressin hormone-V2 receptor-\u03b2-arrestin1 ternary complex","volume":"8","author":"J Bous","year":"2022","journal-title":"Sci Adv"},{"key":"pone.0303507.ref030","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31325-0","article-title":"Structural basis for the activation and ligand recognition of the human oxytocin receptor","volume":"13","author":"Y Waltensp\u00fchl","year":"2022","journal-title":"Nat Commun"},{"key":"pone.0303507.ref031","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41594-022-00728-4","article-title":"The oxytocin signaling complex reveals a molecular switch for cation dependence","volume":"29","author":"JG Meyerowitz","year":"2022","journal-title":"Nat Struct Mol Biol"},{"key":"pone.0303507.ref032","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1021\/jm200278m","article-title":"New, potent, selective, and short-acting peptidic V1a receptor agonists","volume":"54","author":"K Wi\u015bniewski","year":"2011","journal-title":"J Med Chem"},{"key":"pone.0303507.ref033","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41589-021-00930-3","article-title":"Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism","volume":"18","author":"Z Xu","year":"2022","journal-title":"Nat Chem Biol"},{"key":"pone.0303507.ref034","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50279","article-title":"Common activation mechanism of class A GPCRs","volume":"8","author":"Q Zhou","year":"2019","journal-title":"Elife"},{"key":"pone.0303507.ref035","doi-asserted-by":"crossref","first-page":"27849","DOI":"10.1074\/jbc.M112.445098","article-title":"Noncanonical Control of Vasopressin Receptor Type 2 Signaling by Retromer and Arrestin","volume":"288","author":"TN Feinstein","year":"2013","journal-title":"J Biol Chem"},{"key":"pone.0303507.ref036","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142244","article-title":"Monogenic diabetes: a gateway to precision medicine in diabetes","volume":"131","author":"H Zhang","year":"2021","journal-title":"J Clin Invest"},{"key":"pone.0303507.ref037","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41582-020-0409-4","article-title":"Impact of predictive, preventive and precision medicine strategies in epilepsy","volume":"16","author":"R Nabbout","year":"2020","journal-title":"Nature Reviews Neurology"},{"key":"pone.0303507.ref038","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of Precision Cancer Medicine: Evolution of the Treatment Paradigm","volume":"86","author":"AM Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"pone.0303507.ref039","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist","volume":"105","author":"Y Yamamura","year":"1992","journal-title":"Br J Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T17:32:15Z","timestamp":1715794335000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303507"}},"subtitle":[],"editor":[{"given":"Arun","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0303507","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}